EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

Emily Y Chew, Mark Gillies, Glenn J Jaffe, Alain Gaudric, Cathy Egan, Ian Constable, Traci Clemons, Thomas Aaberg, Debora C Manning, Thomas C Hohman, Alan Bird, Martin Friedlander und 1 weitere

NEJM Evidence · 22.07.2025 · 4 (8)

DOI: 10.1056/evidoa2400481 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 22.07.2025. Verfasst von Emily Y Chew und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Ciliary Neurotrophic Factor, Retinal Telangiectasis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ciliary Neurotrophic FactorRetinal TelangiectasisHumansMaleFemaleMiddle AgedVisual AcuityAgedTreatment OutcomeTomography, Optical Coherence

Substanzen

Ciliary Neurotrophic Factor

Autor:innen und Institutionen

  • Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD.
  • Save Sight Institute, University of Sydney, NSW.
  • Department of Ophthalmology, Duke University, Durham, NC.
  • Paris Cité University, Lariboisière Hospital, Greater Paris University Hospitals.
  • Moorfields Eye Hospital, Institute of Ophthalmology, University College London.
  • Lions Eye Institute, University of Western Australia, Perth, WA.

Zitieren

APA

Chew, E. Y., Gillies, M., Jaffe, G. J., Gaudric, A., Egan, C., Constable, I., Clemons, T., Aaberg, T., Manning, D. C., Hohman, T. C., Bird, A., Friedlander, M., & MacTel CNTF NTMT-03 Research investigators (2025). Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. NEJM Evidence, 4(8). https://doi.org/10.1056/evidoa2400481

Vancouver

Chew EY, Gillies M, Jaffe GJ, Gaudric A, Egan C, Constable I, et al. Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. NEJM Evidence. 2025;4(8). doi:10.1056/evidoa2400481

BibTeX
@article{Chew2025,
  author = {Chew, Emily Y and Gillies, Mark and Jaffe, Glenn J and Gaudric, Alain and Egan, Cathy and Constable, Ian and Clemons, Traci and Aaberg, Thomas and Manning, Debora C and Hohman, Thomas C and Bird, Alan and Friedlander, Martin and MacTel CNTF NTMT-03 Research investigators, MacTel CNTF NTMT-03 Research investigators},
  title = {Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2},
  journal = {NEJM Evidence},
  year = {2025},
  volume = {4},
  number = {8},
  doi = {10.1056/evidoa2400481}
}
Kostenlos starten →